Recruiting

EUS-guided nCLE

Sponsor:

Ohio State University Comprehensive Cancer Center

Code:

NCT03492151

Conditions

Pancreatic Cyst

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

The study schema is shown in Figure 4. (A) All patients referred to one of the participating academic centers for EUS evaluation of the PCL will be enrolled in the protocol if they satisfy inclusion criteria. Patient consent will be obtained during the clinic visit or prior to their EUS. EUS-guided nCLE imaging is first performed (B) followed by EUS-guided FNA and aspiration of cyst fluid. The cyst fluid is analyzed for CEA and cytology. As per institutional standard of care, the cyst fluid is also sent for molecular analysis. The results of the cyst fluid molecular analysis (B) will be utilized for the most likely diagnosis. Based on institutional multidisciplinary tumor board meetings, surgery is performed as indicated (C). Surgical histopathology serves as "gold standard" for diagnosis. It is anticipated that the majority of patients will undergo surgical resection after their EUS.

Conditions

Pancreatic Cyst

Study ID

NCT03492151

Start date

Oct 1, 2018

Status verified date

Aug, 2025

Completion date

Dec 31, 2026

Anticipated

Primary completion date

Dec 31, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Patient age 18 years or older
  • All patients referred for EUS-FNA of accessible PCL where surgery is contemplated
  • Minimum cyst size should be ≥ 2.0 cm as determined by prior cross-sectional imaging studies

Exclusion Criteria:

  • Unable to obtain informed consent
  • Unable to tolerate the procedure
  • Women with known pregnancy at time of procedure
  • Patient age less than 18 years
  • Bleeding diathesis
  • Known allergy to fluorescein
  • Prior pancreatic cancer
  • Prior pancreatic surgery

Study Design

Enrollment

500 participants

Anticipated

Interventions and Outcome Measures

Primary outcome measure

  • Accuracy of PCL diagnosis [ Time Frame: 48 months ]
  • Accuracy of risk-stratification of IPMNs [ Time Frame: 48 months ]

Central Contacts and Locations

Central contacts

Locations

Mayo Clinic Scottsdale Campus

Recruiting

Scottsdale, Arizona, United States, 85259

Contacts

Principal Investigator:

Rahul Pannala

Stanford Hospital

Recruiting

Stanford, California, United States, 94305

Contacts

Principal Investigator:

Samer El-Dika

Yale School of Medicine

Recruiting

New Haven, Connecticut, United States, 06510

Contacts

Principal Investigator:

Thiruvengadam Muniraj, MD, MRCP

The Johns Hopkins Hospital

Recruiting

Baltimore, Maryland, United States, 21287

Contacts

Kylie Ning

kning2@jhu.edu

Principal Investigator:

Anne Marie Lennon

Beth Israel Deaconess Medical Center

Recruiting

Boston, Massachusetts, United States, 02215

Contacts

Roya Dastjerdi, MPH

rdastjer@bidmc.harvard.edu

Principal Investigator:

Mandeep Sawhney, MD

NYU Langone Health

Recruiting

Garden City, New York, United States, 11530

Contacts

Maria Marotta-Kollarus

Maria.Kollarus@nyulangone.org

Principal Investigator:

Tomas Gonda, MD

Icahn School of Medicine at Mount Sinai

Recruiting

New York, New York, United States, 10029

Contacts

Principal Investigator:

Frank Gress, MD

The Ohio State University Wexner Medical Center

Recruiting

Columbus, Ohio, United States, 43210

Contacts

Baylor College of Medicine

Recruiting

Houston, Texas, United States, 77030

Contacts

Principal Investigator:

Mohamed Othman, MD

More Information

Sponsor

Ohio State University Comprehensive Cancer Center

Last update posted

Aug 22, 2025

Last verified

Aug, 2025

Keywords

  • Confocal laser endomicroscopy
  • pancreatic cancer
  • IPMN

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Ohio State University Comprehensive Cancer Center on 2025-08-22.